跳至主要内容
临床试验/CTRI/2024/10/075107
CTRI/2024/10/075107尚未招募不适用

To evaluate the irritation potential on healthy human subjects having varied skin types of Skin Care Formulation s

Anivium technologies pvt. ltd1 个研究点 分布在 1 个国家目标入组 26 人开始时间: 2024年10月21日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
26
试验地点
1
主要终点
Dermatological safety of test products, Irritation potential of test products

研究概览

简要总结

Objective: The objective of this study will be to evaluate the irritation potential on healthy human subjects having varied skin types of Skin Care Formulations. 

Duration of study: 8 days study

Kinetics: T0 (Evaluation of test sites by Dermatologist, Patch application) ,T1(Patch removal, Evaluation of test sites by Dermatologist ,T2(Evaluation of test sites by Dermatologist and Subject post 24 hrs of patch removal), T8 (Evaluation of test sites by Dermat and Subject post 1 week of patch removal and tracking the positive cases)

Population: 26 healthy subjects (13 males + 13 females).

The test area is checked for erythema and oedema caused due to the products and compared with positive control

研究设计

研究类型
Interventional
分配方式
Na
盲法
Participant Blinded

入排标准

年龄范围
18.00 Year(s) 至 65.00 Year(s)(—)
性别
All

入选标准

  • Asian Indian male and female subjects 2) Healthy human subjects (no infectious and evolutive pathology which could make the subject vulnerable and stop the study, no pathology which could interfere with the study, no symptom in the process of an exploratory check-up) 3) Between 18 and 65 years of age 4) Skin is healthy on the studied anatomic unit (free of eczema,wounds, inflammatory scar….) 5) Subjects representing varied skin types (ideally equal representation of all 4 skin types – Oily, Normal, Dry and Combination).

排除标准

  • 1 For female: Being pregnant or breastfeeding or having stopped to breastfeed in the past three months 2 Having refused to give his/her assent by not signing the consent form 3 Taking part in another study liable to interfere with this study 4 Being diabetic.
  • 5 Being asthmatic.
  • 6 Following a chronic medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, antihistamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol).
  • 7 Having cutaneous hypersensitivity (except in the case of studies with evaluation of sensitive skin).
  • 8 Having a diagnosed or highly probable allergy to one or several compounds of the cosmetic products.
  • 9 Having undergone a surgery requiring a general anaesthesia of more than one hour in the past 6 months.
  • 10 Having changed his/her cosmetic habits in the 14 days preceding the start of the study on the studied anatomic unit.

结局指标

主要结局

Dermatological safety of test products, Irritation potential of test products

时间窗: Baseline, 0 hr , 24 hours & day 8

次要结局

未报告次要终点

研究者

发起方
Anivium technologies pvt. ltd
申办方类型
Other [fmcg]
责任方
Principal Investigator
主要研究者

Dr Pooja Yadav

MASCOT-SPINCONTROL India Pvt. Ltd.

研究点 (1)

Loading locations...

相似试验

Safety check of Skin care products | 临床试验